Luke Miller was named senior vice president of lab operations of Avomeen in Ann Arbor and will strengthen and expand its laboratory operations to support continued growth.
Avomeen is an accredited, independent contract research and contract development and manufacturing organization. It brings chemists and scientists together to think through chemical issues across industries and applications.
“Luke brings a wealth of knowledge and expertise in operations strategy, team development, and lab design and optimization,” says Mark Harvill, CEO of Avomeen. “His leadership and expertise will be invaluable as we continue to grow and expand our life sciences and nicotine service offerings and teams, ensuring our clients receive the exceptional service they have come to expect from Avomeen.”
Miller recently served as the vice president of lab operations at Metabolon. He co-developed and launched an assay for inborn error of metabolism screening; co-developed and launched a platform for analysis of complex lipids in mammalian samples; and extracted, identified, and patented a previously unidentified, novel biomarker for insulin resistance. Prior to this, he held a position as a director of analytical chemistry in drug discovery at GlaxoSmithKline.
Throughout his career, he has developed expertise in engineering and oversight of high-volume, high-throughput labs, including instruments, consumables, process optimization, and others.
Miller holds a doctorate degree in analytical chemistry from the University of Reading, United Kingdom and a bachelor’s degree in chemistry and management from City University of London.
Miller comes to Avomeen with more than 25 years of experience in lab operations and leadership.
